EBODAC

EBODAC – Vaccine Deployment, Acceptance and Compliance

 

The EBODAC project is developing strategies and tools to promote the acceptance and uptake of new Ebola vaccines, to help the right person receive the right vaccine at the right time.

 

EBODAC is important because the successful development and deployment of an Ebola vaccine is faced with many challenges, especially when working in resource limited settings. These include:

 

EBODAC is working to ensure the novel prime-boost vaccine regimen is well accepted and successfully used in the context of clinical trials; while also preparing to maximise the impact of the potential deployment of a future Ebola vaccination programme in West Africa.

 

EBODAC is currently supporting the EBOVAC-Salone clinical trial in Kambia District, Sierra Leone, and is using this opportunity to evaluate the three levers it has developed:

 

All components of the EBODAC platform are designed and developed to allow rapid scale-up should there be a need to eventually deploy a licensed vaccine.

a1-female-participant-receives-motech-message-credit-anneleen-vuchelen-janssen-1

EBOVAC-Salone participant receives mobile phone message supplied by the EBODAC project. (Credit: Anneleen Vuchelen)

EBODAC Symposium

The EBODAC consortium held a symposium on Communications, Community Engagement and Technologies in Ebola Clinical Trials on 20/21 February 2017. More information is available here.

These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
www.imi.europa.eu
Copyright © 2017 Ebovac | Terms and Conditions | WordPress development by Toast.